New Study From CVS Caremark and Employee Benefit News Shows How Employers Rely on Their Pharmacy Benefit Manager To Create Sustainable Pharmacy Solutions
CVS Caremark released survey results conducted with Employee Benefit News showing that 91% of employers are concerned about high medication costs and view PBMs as essential partners for reducing expenses. The company highlighted its biosimilar strategy, noting that since April 2024, formulary changes have generated over $3.3 billion in gross savings on Humira, while a recent transition to Stelara biosimilars offers $0 out-of-pocket costs for most members.
Key figures
- Clinics
- 1000
- Plan members
- 87000000
- Retail locations
- 9000
- Insurance members
- 37000000
- Glp1 program savings
- 26%
- Gross savings humira
- $3.3 billion
- Annual tech investment
- $770 million
- Employers see pbm value
- 88%
- Employers concerned glp1 cost
- 77%
- Employers concerned drug prices
- 91%
- Employers limiting glp1 coverage
- 80%
- Employers pbm access opportunity
- 64%
- Employers encouraging biosimilars
- 49%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.